| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| Q4081 |
Injection, epoetin alfa, 100 units (for esrd on dialysis) |
7,202 |
254 |
$1.12M |
| 90999 |
|
6,944 |
352 |
$1.10M |
| J1270 |
Injection, doxercalciferol, 1 mcg |
2,700 |
160 |
$448K |
| A4657 |
Syringe, with or without needle, each |
542 |
278 |
$160K |
| 85048 |
|
375 |
238 |
$55K |
| 85041 |
|
375 |
238 |
$55K |
| 82728 |
|
120 |
80 |
$19K |
| 83970 |
|
106 |
66 |
$19K |
| 83540 |
|
99 |
66 |
$14K |
| 83550 |
|
93 |
62 |
$14K |
| J1756 |
Injection, iron sucrose, 1 mg |
78 |
12 |
$5K |
| 82108 |
|
34 |
24 |
$4K |
| G0499 |
Hepatitis b screening in non-pregnant, high risk individual includes hepatitis b surface antigen (hbsag), antibodies to hbsag (anti-hbs) and antibodies to hepatitis b core antigen (anti-hbc), and is followed by a neutralizing confirmatory test, when performed, only for an initially reactive hbsag result |
22 |
13 |
$0.00 |